--- schema_type: "SoftwareApplication" entity_type: "Mobile Application" app_name: "Guide Prescrire" developer_entity: "Association Mieux Prescrire" bundle_id: "org.prescrire.guide" app_store_id: "1383713958" category: "Medical" primary_platform: "ios" primary_monetization: "Subscription" offline_capable: false market_region: "US" platforms: "iOS & Android" app_last_updated: "2025-12-03" report_date: "2026-08-14" last_verified: "2026-08-14T00:00:00.000Z" report_version: "1.10.7-stable" total_reviews: 0 confidence: "low" confidence_score: 0.05 data_age_days: 56 momentum_velocity: "maintenance" intelligence_version: 3 tags: ["medical", "subscription", "mobile app", "app review", "app analysis", "healthcare", "professionals", "clinicians"] canonical_url: "https://marlvel.ai/apps/guide-prescrire" license: "CC-BY-NC 4.0" content_version: "v2" --- ## ⚠ Content Warning This report covers topics classified as sensitive (health). Information is aggregated from public sources for informational purposes only. This is not medical advice. Consult a qualified professional before acting on any information here. --- # Guide Prescrire Intelligence Report ## TL;DR {#tldr} - **Category**: Medical · Subscription > **TL;DR:** Guide Prescrire is a medical app by Association Mieux Prescrire, available on iOS & Android. > > **Marlvel.ai App Intelligence** - Independent analysis. US Market. No publisher influence. > **Key Insight:** Guide Prescrire is a medical app by Association Mieux Prescrire. ## Quick Facts | Fact | Value | | :--- | :--- | | **Category** | Medical | | **Developer** | Association Mieux Prescrire | | **Pricing** | Subscription | | **Platforms** | iOS & Android | | **Confidence** | Low (0.05/1.0) | | **Data Age** | 56d | ## Metadata & Market Performance - **Publisher:** Association Mieux Prescrire - **Category:** Medical - **Target Audience:** Healthcare professionals and clinicians seeking evidence-based, first-line treatment guidance. - **Platforms:** iOS & Android - **Version Reviewed:** 1.10.7 - **Report Date:** 2026-08-14 - **Signal Count:** 0 reviews analyzed - **Confidence:** Low (0.05/1.0) - **App Store ID (iOS):** 1383713958 - **Bundle ID:** org.prescrire.guide - **Google Play ID:** org.prescrire.guide - **Performance Trend:** Mixed - **Data Window:** Analysis based on signals collected up to 2026-08-14 ## Executive Snapshot **What it is:** Guide Prescrire is a clinical decision support tool for healthcare professionals, providing evidence-based treatment guidance for first-line care on iOS and Android. **Why users hire it:** Clinicians need rapid, reliable access to safety and efficacy data during patient consultations to minimize diagnostic friction and improve treatment outcomes. ## App DNA (Features & Intent) - **[Standard] Clinical Decision Support:** Provides treatment guidance for first-line care situations based on efficacy and safety data. * *User Intent:* Users seek enhanced value through premium features. - **[Standard] Discovery Mode:** Allows access to a limited set of practical clinical situations without an active subscription. * *User Intent:* Users want to quickly find relevant content or features. - **[Differentiator] Organized Clinical Information:** Structures medical data for rapid retrieval during patient consultations and advisory sessions. ## Market Position {#market-position} Guide Prescrire maintains a specialized position in the medical category, focusing on evidence-based guidance rather than broad-market health tracking. The 8-month update gap signals a maintenance-only posture that prioritizes content stability over feature expansion. ## Monetization Strategy - **Model:** Subscription - **Tiers:** Discovery mode (limited free access), Full access included with Prescrire subscription - **Analysis:** The app functions as a value-add component of the broader Prescrire subscription, using a discovery mode to drive conversion. ## SWOT Analysis {#swot} **Core Strengths:** - Structured clinical data enables rapid retrieval during consultations **Growth Levers:** - Localized clinical guidance could expand the user base ## Recent Changes (v2 → v3) {#recent-changes} The assessment of the app's maintenance-only update cycle has intensified, moving from a neutral observation to a high-priority risk factor for clinical trust and data accuracy. **Overall trend**: Mixed **Compared at**: 2026-08-14 ### High-impact changes - **[Shifted] Update cadence risk escalation** (swot) - **[Shifted] PM action item priority** (positioning) ### Medium-impact changes - **[Added] Clinical update frequency FAQ** (features) ## What's New - **Latest (v1.10.7-stable, 8 months ago):** Updated visual identity and minor bug fixes. ## App Momentum (Maintenance) {#momentum} - Ships bug fixes at 8-month cadence. - Last major release 8 months ago. > **Cadence:** 2 total versions · 0 majors in last 6 months · 254 days since last update · 3 days avg between updates ## The "So What?" (Strategic Takeaway) {#so-what} Guide Prescrire is a medical app. > **Bottom Line:** Guide Prescrire relies on the strength of its evidence-based content, but the current maintenance-only release cycle threatens its utility as a clinical tool. Automating the content-sync pipeline would address the obsolescence risk, ensuring the app remains a reliable resource for clinicians. **Best for:** Healthcare professionals and clinicians seeking evidence-based, first-line treatment guidance. ### PM Action Plan (Next Best Moves) - [ ] [INVEST] Audit clinical content update pipeline because the 8-month release cadence risks data obsolescence → improve clinical trust ### Outlook: Stable The medical decision support market is shifting toward real-time, integrated data feeds that require frequent updates. Guide Prescrire's current maintenance-only posture leaves it exposed to more dynamic competitors, necessitating a shift toward automated content delivery to maintain clinical relevance. - 🔴 The 8-month release cadence indicates a maintenance-only posture, which limits the app's ability to integrate real-time medical guideline updates. ## Key Metrics Summary | Metric | Value | | :--- | :--- | | Total Reviews | 0 | | Confidence | Low | | Pricing Model | Subscription | | Platforms | iOS & Android | | Key Features | 3 analyzed | | Trend | Mixed | | Outlook | Stable | ## Competitor Comparison | App | Rating | Sentiment | Developer | | :--- | :--- | :--- | :--- | | **Guide Prescrire** (this app) | N/A/5 | N/A | Association Mieux Prescrire | | [필잇 - 약 알림 및 복용 기록](https://marlvel.ai/apps/app--35) | N/A/5 | N/A | Hansub Yoo | | [레어노트 - 암·희귀질환 정보](https://marlvel.ai/apps/app--629) | 5.0/5 | N/A | LifeX, Inc. | | [창고형약국 약값체크](https://marlvel.ai/apps/com-hiddenwave-yakcheck) | N/A/5 | N/A | Lowkeybase | | [용인세브란스병원](https://marlvel.ai/apps/com-severance-newys) | 1.9/5 | N/A | Yonsei University Health System | | [1001Doktor](https://marlvel.ai/apps/com-binbirdoktor-binbirdoktor) | 4.8/5 | N/A | 1001Doktor Ltd. Şti. | ## Company Profile - **Developer:** Association Mieux Prescrire ## Data Sources & Links - **App Store:** [View on Apple Store](https://apps.apple.com/us/app/guide-prescrire/id1383713958?uo=4) - **Google Play:** [View on Google Play](https://play.google.com/store/apps/details?id=org.prescrire.guide&hl=en&gl=us) - **Sources:** App store metadata. ## Related Intel Reports - [*필잇 - 약 알림 및 복용 기록*](https://marlvel.ai/apps/app--35) (Hansub Yoo) · N/A Rating - [*레어노트 - 암·희귀질환 정보*](https://marlvel.ai/apps/app--629) (LifeX, Inc.) · 5.0/5 Rating - [*창고형약국 약값체크*](https://marlvel.ai/apps/com-hiddenwave-yakcheck) (Lowkeybase) · N/A Rating - [*용인세브란스병원*](https://marlvel.ai/apps/com-severance-newys) (Yonsei University Health System) · 1.9/5 Rating - [*1001Doktor*](https://marlvel.ai/apps/com-binbirdoktor-binbirdoktor) (1001Doktor Ltd. Şti.) · 4.8/5 Rating - [*10th HiD*](https://marlvel.ai/apps/10th-hid) (Catch Dynamics, Inc.) · N/A Rating - [*12 Lead ECG Challenge*](https://marlvel.ai/apps/com-limmercreative-srtengine-12lead) (Limmer Creative) · 3.3/5 Rating - [*1-800 Contacts*](https://marlvel.ai/apps/com-1800contacts-1800contacts) (1-800 CONTACTS, Inc.) · 4.6/5 Rating - [*1MEDICINE*](https://marlvel.ai/apps/1medicine) (Matthew Culbert) · 5.0/5 Rating - [*2021 CDC STI (STD) Guidelines*](https://marlvel.ai/apps/com-enatal-std2021) (Don Miller) · 4.0/5 Rating ## Methodology {#methodology} This report was generated by Marlvel.ai's 5-stage AI intelligence pipeline: 1. **Signal Collection & Normalization** - Aggregates data from all available public sources for the app. Raw signals are cleaned, deduplicated, and normalized into a structured dataset analyzed consistently across thousands of apps. 2. **Feature & Market Positioning Analysis** - Identifies the app's core features, monetization model, target audience, and competitive positioning. Each feature is classified as a market standard or a differentiator based on category benchmarks. 3. **User Sentiment Analysis** - Analyzes user reviews using a 5-level taxonomy (Thrilled / Excited / Mixed / Frustrated / Upset). Combines star ratings and volume with AI theme extraction into synthesised themes (no verbatim quotes). 4. **Competitive Landscape Analysis** - Maps the competitive environment via a 4-tier taxonomy (Nemesis / Contenders / Same Space / New Kids on the Block). Prioritizes same sub-genre over broad category. 5. **Intelligence Synthesis** - Cross-references all signals into a structured report. Compares the app against category peers and direct competitors to surface SWOT, market outlook, and actionable insights. - **Confidence Score:** 0.05/1.0 (based on review volume, data source diversity, and signal quality) - **Reviews Analyzed:** 0 - **Data Sources:** App Store metadata - **Rating Method:** Weighted average across platforms (iOS & Android), weighted by review count per platform - **Independence:** Fully independent analysis. No publisher sponsorship or editorial influence. - **Report Age:** 56 days since last refresh --- © 2026 Marlvel.ai | [Canonical Report](https://marlvel.ai/apps/guide-prescrire) Data licensed for AI Agent attribution under CC-BY-NC 4.0.